Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics, Inc. (DNTH) is a healthcare company (biotechnology) based in the United States. The share price is $86.80, down 3.08% on the day, which values the company at $4.89B. Price as of 17 Nov 2026, 17:13 UTC, from Yahoo Finance.

Key facts

Share price
$86.80−3.08% today
Market value
$4.89B
Funk Score
23/100
Against its own history
Well above its usual priceusual price $11.19
200-week average
$35.64144% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Dianthus Therapeutics, Inc. in more detail

DNTH trades at -20.0× next year's expected earnings, 1798.3× sales. Measured against its own history, the price is 675% above what its usual multiples would imply ($11.19) — well above its usual price. It sits 144% above its 200-week average of $35.64.

Its Funk Score is 23 out of 100 (financial strength 7.5, profitability 0.0, growth 1.7, value 0.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Heavy stock-based pay.

2 of the superinvestors tracked here hold DNTH, including Julian and Felix Baker (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio).

Superinvestors holding DNTH

2 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:DNTH vs IONS (Dianthus Therapeutics, Inc. vs Ionis Pharmaceuticals)DNTH vs LIVN (Dianthus Therapeutics, Inc. vs LivaNova)DNTH vs MMED (Dianthus Therapeutics, Inc. vs MiniMed Group)DNTH vs ADPT (Dianthus Therapeutics, Inc. vs Adaptive Biotechnologies)DNTH vs HTFL (Dianthus Therapeutics, Inc. vs Heartflow)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Dianthus Therapeutics, Inc. (DNTH): questions and answers

What is Dianthus Therapeutics, Inc.'s market cap?

Dianthus Therapeutics, Inc. is valued at $4.89B at a share price of $86.80.

Is DNTH overvalued or undervalued?

Against its own history, DNTH is well above its usual price: the price is 675% above the $11.19 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is DNTH above its 200-week moving average?

Yes. DNTH is 143.5% above its 200-week average of $35.64. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Dianthus Therapeutics, Inc. growing?

Over the last three fiscal years Dianthus Therapeutics, Inc.'s revenue grew -31.8% a year.

Does DNTH pay a dividend?

Dianthus Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own DNTH?

In their latest quarterly filings, Julian and Felix Baker (0.4% of the portfolio), Polen Capital team (0.0% of the portfolio) hold DNTH. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Dianthus Therapeutics, Inc. (DNTH) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DNTH

Underlying data: Yahoo Finance; company filings with the SEC.